News

Masitinib study misses endpoint
Enlarge image

Clinical trailsFrance

Masitinib study misses endpoint

01.11.2012 - French AB Science’s cancer drug Masitinib failed to improve overall survival in a Phase III study. But certain patient groups might benefit from the treatment.

The double-blind, international Phase III trial enrolled 348 patients with pancreatic cancer and compared masitinib plus Gemzar treatment with Gemzar treatment alone. There was no significant change in the overall survival time of the patients (7.7 vs. 7 months, p=0.74), said the French drugmaker. But in a subgroup of patients with an undisclosed genetic biomarker which is thought to be indicative of aggressive disease progression, the orally administered tyrosine kinase inhibitor masitinib plus Gemzar significantly improved median overall survival vs. placebo plus Gemzar (11 vs. 5 months, p=0.000038). In a second subgroup of patients with a pain intensity level above an undisclosed threshold at baseline, the orphan drug plus Gemzar also significantly improved median overall survival vs. placebo plus Gemzar (8.1 vs. 5.4 months, p=0.01). These two independent patient populations represented 65% and 45%, respectively, of the overall population, according to AB Science.

AB Science also announced that the European Medicines Agency (EMA) has accepted to review the Marketing Authorization Application (MAA) for conditional approval of masitinib in combination with Gemzar in the treatment of non-resectable, advanced adenocarcinoma pancreatic cancer „ on the basis of results from a Phase III study that showed masitinib in combination with Gemzar significantly extends overall survival in two independent patient populations having the worst prognosis.“ Masitinib targets the stem cell factor (SCF) receptor tyrosine kinase (CD117).

Masitinib has been available in Europe since the second part of 2009 as a treatment of mast cell tumors in animals (Masivet), specifically dogs. In the US it is distributed under the name Kinavet by AB Science and has been available for veterinaries since 2011.

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-04/masitinib-study-misses-endpoint.html

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOLVA1.67 CHF7.74%
  • VITA 345.75 EUR6.48%
  • PAION2.15 EUR4.37%

FLOP

  • WILEX3.16 EUR-7.87%
  • MAGFORCE5.65 EUR-1.74%
  • FORMYCON16.51 EUR-1.14%

TOP

  • WILEX3.16 EUR60.4%
  • BASILEA121.50 CHF15.7%
  • EVOLVA1.67 CHF14.4%

FLOP

  • SANTHERA96.00 CHF-12.6%
  • 4SC0.79 EUR-9.2%
  • MOLOGEN5.40 EUR-4.4%

TOP

  • SANTHERA96.00 CHF2367.9%
  • WILEX3.16 EUR435.6%
  • FORMYCON16.51 EUR104.3%

FLOP

  • CYTOS0.34 CHF-88.7%
  • MOLOGEN5.40 EUR-55.6%
  • BIOFRONTERA1.90 EUR-51.8%

No liability assumed, Date: 01.03.2015